SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
MWN-AI** Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), a biopharmaceutical company specializing in cancer therapies, has announced that it will present preclinical data on its lead candidate, SLS009 (tambiciclib), at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. This event is scheduled for May 30 to June 3, 2025, in Chicago, Illinois. The specific poster presentation will occur on June 2, 2025, from 1:30 PM to 4:30 PM CDT, focusing on the in vitro efficacy of SLS009 in colorectal cancer cell lines with ASXL1 mutations.
SLS009 is currently the subject of a Phase 2 clinical trial investigating its combined safety and efficacy with venetoclax and azacitidine in adults with acute myeloid leukemia (AML), particularly those with ASXL1 mutations linked to poor prognoses. The trial also aims to identify biomarkers that could enhance patient selection for further studies.
Evidence suggests that SLS009 may exhibit significant response rates in AML patients characterized by unfavorable prognostic factors. This potential distinction from other CDK9 inhibitors speaks to its promise as a targeted treatment option.
Meanwhile, SELLAS continues to advance its lead product, GPS, a therapy targeting the WT1 protein, which is relevant for a variety of tumors. The company is dedicated to developing innovative treatments, and as a late-stage enterprise, it is actively working to address important unmet medical needs within oncology.
The full abstract detailing SLS009's preclinical study will be available on ASCO's website on May 22, 2025. Stakeholders and those interested in developing treatments for cancer can stay informed by accessing additional information through SELLAS's official website.
MWN-AI** Analysis
As SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) approaches its presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, it presents both an opportunity and caution for investors. The presentation of preclinical efficacy data on SLS009, a novel CDK9 inhibitor for ASXL1 mutated colorectal cancer, paired with ongoing studies into its efficacy in combination therapies, positions SELLAS at the forefront of targeted cancer therapies.
The upcoming poster presentation is likely to generate significant interest, particularly given the emphasis on identifying biomarkers associated with ASXL1 mutations—an area of critical focus in oncological research. Consequently, should the data presented demonstrate promising results, it's plausible that SELLAS could experience a surge in investor confidence, potentially increasing share prices.
However, investors should remain wary of the inherent risks associated with biotechnology investments. Clinical trials, especially in oncology, are fraught with uncertainty. The efficacy and safety data from SLS009 in its ongoing Phase 2 study may not meet expectations, and regulatory hurdles could pose additional challenges. With these considerations in mind, potential volatility is expected as the market reacts to the presentation and subsequent disclosures.
Moreover, driven by the dynamics of investor sentiment and market trends, investors should consider employing a balanced approach. A strategic entry point in SELLAS shares could capitalize on potential price increases post-ASCO while maintaining the flexibility to manage risk exposure. Investors might also watch for analyst ratings and institutional buy-in following the ASCO presentation.
In summary, while SELLAS presents a compelling investment opportunity due to its innovative pipeline and upcoming visibility at ASCO, careful assessment of risks and diligent monitoring of market reactions are essential for any prudent investment strategy. Investors should stay informed and prepared to act based on the unfolding data narratives and market conditions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical efficacy of SLS009 in ASXL1 mutated colorectal cancer lines will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 30- June 3, 2025 in Chicago, Illinois.
Poster presentation details:
Title: In vitro efficacy of CDK9 inhibitor tambiciclib (SLS009) in ASXL1 mutated colorectal cancer cell lines.
Session Date and Time: Monday, June 2, 2025, 1:30 PM-4:30 PM CDT
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Location: Hall A - Posters and Exhibits
Abstract #: 3121
Poster Board #: 436
The full text of the abstract will be released by ASCO on May 22, 2025, at 5:00 PM EDT on asco.org/abstracts.
SLS009 is currently being investigated in a Phase 2 open-label, single-arm, multi-center study designed to evaluate the safety, tolerability, and efficacy of SLS009 in combination with venetoclax and azacitidine including AML patients with ASXL1 mutations. Initial clinical safety and efficacy data are available. In addition, the study aims to identify biomarkers for the target patient population and enrichment for further trials. For more information on the study, visit clinicaltrial.gov identifier NCT04588922 .
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 20, 2025 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.
Investor Contact
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
FAQ**
What specific preclinical results will SELLAS Life Sciences Group Inc. SLS present regarding the efficacy of SLS009 in ASXL1 mutated colorectal cancer lines at the 2025 ASCO Annual Meeting?
How does SELLAS Life Sciences Group Inc. SLS plan to leverage the initial clinical safety and efficacy data from its Phase 2 study of SLS009 in combination with venetoclax and azacitidine moving forward?
What strategies does SELLAS Life Sciences Group Inc. SLS have in place to identify biomarkers for the target patient population during the SLS009 study to enhance future clinical trials?
Can you elaborate on the potential market impact and competitive advantages of SLS009 as a best-in-class CDK9 inhibitor compared to existing therapies in treating AML patients with ASXL1 mutations?
**MWN-AI FAQ is based on asking OpenAI questions about SELLAS Life Sciences Group Inc. (NASDAQ: SLS).
NASDAQ: SLS
SLS Trading
20.38% G/L:
$6.97 Last:
7,820,479 Volume:
$6.48 Open:
